Department of Oncology Services, Christchurch Hospital, Christchurch, New Zealand.
Medical Physics and Bioengineering, Christchurch Hospital, Christchurch, New Zealand.
J Med Radiat Sci. 2022 Dec;69(4):502-509. doi: 10.1002/jmrs.597. Epub 2022 May 23.
Deep inspiratory breath-hold (DIBH) has become standard in radiotherapy for left-sided breast cancer to reduce the heart dose. This study evaluated breath-hold stability and reproducibility using Elekta's Active Breathing Coordinator™ (ABC) and its effectiveness and feasibility in left-sided breast cancer patients undergoing radiotherapy.
Eligible patients were planned with free breathing (FB) and DIBH protocols. DIBH treatment was considered if the mean heart dose (MHD) was ≥2 Gy on the FB plan. Those who proceeded with DIBH treatment were enrolled for the pilot study. Electronic portal images of DIBH treatment beams were taken using the movie-exposure mode for breath-hold stability and reproducibility analysis. DIBH effectiveness in heart dose reduction and impact on simulation and treatment durations were compared with FB protocol.
Out of 56 eligible patients, 15 proceeded with DIBH treatment. The mean difference of patient setup within a single breath-hold was 0.4 mm; between different breath-holds of the same beam 1.1 mm and between different days 2.6 mm. DIBH reduced the MHD by 47% and the mean left anterior descending artery (LAD) dose by 35%. DIBH took longer time than FB in simulation and treatment. At least 14% of the eligible patients did not tolerate DIBH during simulation.
ABC leads to stable and reproducible breath-holds and results in significant heart dose reductions. It may not be tolerated by all patients and has resource implications.
深吸气屏气(DIBH)已成为左侧乳腺癌放疗的标准方法,以降低心脏剂量。本研究使用 Elekta 的主动呼吸控制器(ABC)评估屏气的稳定性和可重复性,并评估其在接受放疗的左侧乳腺癌患者中的有效性和可行性。
符合条件的患者分别进行自由呼吸(FB)和 DIBH 计划。如果 FB 计划中的平均心脏剂量(MHD)≥2Gy,则考虑进行 DIBH 治疗。如果选择 DIBH 治疗,则纳入该研究的试点阶段。使用电影曝光模式拍摄 DIBH 治疗射束的电子端口图像,用于分析屏气的稳定性和可重复性。比较 DIBH 在降低心脏剂量方面的有效性以及对模拟和治疗时间的影响与 FB 方案。
在 56 名符合条件的患者中,有 15 名患者接受了 DIBH 治疗。单次屏气期间患者摆位的平均差异为 0.4mm;同一射束的不同屏气之间为 1.1mm,不同天之间为 2.6mm。DIBH 使 MHD 降低了 47%,使左前降支(LAD)的平均剂量降低了 35%。DIBH 比 FB 在模拟和治疗过程中花费的时间更长。在模拟过程中,至少有 14%的符合条件的患者不能耐受 DIBH。
ABC 可实现稳定且可重复的屏气,并显著降低心脏剂量。但并非所有患者都能耐受 DIBH,且可能需要更多资源。